Why Is Alphatec Holdings (ATEC) Stock Down -30% Today?
Key Takeaways
- ATEC shares plunged 30.55% to close at $7.11 from the previous close of $10.23.
- Primary catalyst: Q1 2026 earnings miss with revenue of $192 million versus expectations of $197.5 million, driven by weakness in EOS imaging sales.
- EPS of -$0.22 missed consensus of -$0.01; company lowered full-year EOS revenue guidance to $77 million while maintaining surgical revenue outlook at $805 million.
- Trading volume spiked to over 14 million shares, well above the average of 2.66 million, indicating heavy selling pressure.
- Move diverged sharply from broader market, with Nasdaq up over 1% and medical devices ETF (IHI) down only 0.28%.
- Traders watching EOS business recovery, Q2 execution, and surgeon adoption metrics ahead of next earnings in late July.
Breaking Down the Sharp Decline in ATEC
I've been keeping an eye on ATEC, the medical technology company focused on spinal implants, instruments, biologics, and imaging systems for spine surgery. Yesterday, its shares fell 30.55%, closing at $7.11 after the prior session's $10.23. The market's reaction came right after the Q1 2026 earnings release on May 5, triggered by a revenue miss and reduced guidance for the EOS imaging segment—even as the core surgical business showed solid growth.
The Earnings Details and Guidance Shift
Alphatec posted Q1 revenue of $192.1 million, a 14% increase year-over-year, but it fell short of the $197.5 million consensus. The surgical revenue segment, which forms the backbone of the business, grew 17% to $178 million, fueled by 21% higher case volumes and 23% more surgeons, particularly in lateral, ALIF, and cervical procedures. That said, EOS imaging revenue dropped 18% to $14 million, mainly from fewer system deliveries, which pulled the overall numbers down.
On the bottom line, GAAP EPS was -$0.22, missing the expected -$0.01 loss. The net loss improved to $33.9 million from $51.9 million last year, thanks to reduced litigation costs. Adjusted EBITDA rose to $21 million. Management noted that EOS fell short of internal goals and plans to ramp up sales and marketing efforts there.
For the full year, guidance now calls for $882 million in total revenue (15% growth), with surgical revenue unchanged at $805 million (17% growth) and EOS trimmed to $77 million. The adjusted EBITDA target remains $134 million, signaling confidence in margin expansion.
Trading Volume and Broader Market Comparison
Trading volume surged to 14 million shares—more than five times the average of 2.66 million—reflecting the strong investor response. The drop gapped shares below recent support at $9-10, approaching 52-week lows of $6.85-9.11. What stands out is how ATEC diverged from peers: the IHI medical devices ETF dipped only 0.28%, while the XLV healthcare ETF rose 0.39%. The Nasdaq Composite gained 1.03%, and the S&P 500 advanced 0.81%, pointing to company-specific concerns.
What I'm Watching for ATEC's Recovery
From what I see, the key will be EOS sales rebounding through enhanced sales initiatives and sustained procedure growth in Q2. The next earnings report is due in late July, where execution against the $882 million revenue and $134 million adjusted EBITDA goals will be critical. Analysts hold a bullish consensus with average price targets around $23-24, though adjustments like Canaccord's cut to $23 highlight EOS worries. Spine surgery innovation offers sector tailwinds, but risks from high debt and competition—such as from GMED—remain. Macro factors and healthcare demand will also play a role.
I also checked this using Tickeron’s AI Screener to compare ATEC against industry peers, which helped contextualize the surgical segment's strength.
Why I Rely on Tickeron's Trending AI Robots
In my own trading and research, I often turn to Tickeron’s Trending AI Robots page to spot top-performing AI-driven bots amid shifting markets. Tickeron runs hundreds of these bots across thousands of tickers, using strategies like trend-following, mean reversion, and momentum on various timeframes. The trending list focuses on those with the best risk-adjusted returns, win rates, and consistency—backed by metrics like Sharpe ratio, maximum drawdown, and profit factor. I've found it useful to test them in virtual portfolios before going live; it's a practical way to sharpen my edge without starting from scratch.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
ATEC's Indicator enters downward trend
The Aroon Indicator for ATEC entered a downward trend on May 14, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 196 similar instances where the Aroon Indicator formed such a pattern. In of the 196 cases the stock moved lower. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on April 27, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ATEC as a result. In of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ATEC turned negative on May 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATEC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ATEC's RSI Indicator exited the oversold zone, of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where ATEC advanced for three days, in of 309 cases, the price rose further within the following month. The odds of a continued upward trend are .
ATEC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ATEC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ATEC's P/B Ratio (128.205) is very high in comparison to the industry average of (12.607). P/E Ratio (0.000) is within average values for comparable stocks, (50.865). ATEC's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.650). ATEC has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.023). P/S Ratio (1.461) is also within normal values, averaging (36.374).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATEC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a holding company with interests in medical equipment and supplies
Industry MedicalNursingServices
Advertisement